Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 86.1 -4.15% -3.73
NBIX closed up 5.89 percent on Thursday, March 21, 2019, on 1.5 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical NBIX trend table...

Date Alert Name Type % Chg
Mar 21 New Uptrend Bullish -4.15%
Mar 21 180 Bullish Setup Bullish Swing Setup -4.15%
Mar 21 Pocket Pivot Bullish Swing Setup -4.15%
Mar 21 Upper Bollinger Band Walk Strength -4.15%
Mar 21 Multiple of Ten Bearish Other -4.15%
Mar 21 Weak + Overbought Other -4.15%
Mar 21 Above Upper BB Strength -4.15%
Mar 21 Overbought Stochastic Strength -4.15%
Mar 21 Upper Bollinger Band Touch Strength -4.15%
Mar 20 Stochastic Sell Signal Bearish 1.50%

Older signals for NBIX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Chemistry Pain Diabetes Disorders Schizophrenia Alcohols Cardiovascular Diseases Hormones Epilepsy Ethers Movement Disorders Ii Diabetes Pyrimidines Gnrh Antagonists Insomnia Endometriosis Gonadotropin Releasing Hormone Antagonist Uterine Fibroids
Is NBIX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 126.98
52 Week Low 64.72
Average Volume 917,915
200-Day Moving Average 98.3635
50-Day Moving Average 84.0448
20-Day Moving Average 81.075
10-Day Moving Average 83.623
Average True Range 2.9396
ADX 25.1
+DI 30.6556
-DI 14.25
Chandelier Exit (Long, 3 ATRs ) 81.6612
Chandelier Exit (Short, 3 ATRs ) 83.5188
Upper Bollinger Band 88.6151
Lower Bollinger Band 73.5349
Percent B (%b) 1.08
BandWidth 18.600308
MACD Line 1.2078
MACD Signal Line -0.0222
MACD Histogram 1.23
Fundamentals Value
Market Cap 7.92 Billion
Num Shares 88.2 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -35.65
Price-to-Sales 826.51
Price-to-Book 15.16
PEG Ratio 1.78
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 96.00
Resistance 3 (R3) 95.53 93.00 94.97
Resistance 2 (R2) 93.00 91.43 93.24 94.62
Resistance 1 (R1) 91.42 90.46 92.21 91.89 94.28
Pivot Point 88.89 88.89 89.29 89.13 88.89
Support 1 (S1) 87.31 87.32 88.10 87.78 85.38
Support 2 (S2) 84.78 86.35 85.02 85.04
Support 3 (S3) 83.20 84.78 84.69
Support 4 (S4) 83.67